Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Selecta Biosciences (NQ: SELB )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Selecta Biosciences

< Previous 1 2 3 4 Next >
41 Stocks Moving In Wednesday's Mid-Day Session
Gainers Asensus Surgical, Inc. (NYSE: ASXC) shares surged 34.4% to $2.7282. HC Wainwright & Co. initiated coverage on Asensus Surgical with a Buy rating and announced a price... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS) stock moved upwards by 20.74% to $4.54 during Wednesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
22 Stocks Moving in Wednesday's Pre-Market Session
Gainers Nabriva Therapeutics plc (NASDAQ: NBRV) rose 48.8% to $2.20 in pre-market trading. Sinovant Sciences and Nabriva Therapeutics disclosed topline results from Phase 3 trial... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS 
Via Benzinga
ROCE Insights For Selecta Biosciences
Selecta Biosciences (NASDAQ:SELB) reported Q1 sales of $11.05 million. Earnings fell to a loss of $7.16 million, resulting in a 9.37% decrease from last quarter. Selecta... 
Via Benzinga
Recap: Selecta Biosciences Q1 Earnings
Shares of Selecta Biosciences (NASDAQ:SELB) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were down 4.76% year over year... 
Via Benzinga
Is It Time to Buy These 3 Stocks?
It may be time to buy Twitter, Inc. (NYSE:TWTR), Sel... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million. •... 
Via Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
65 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 33.1% to settle at $3.34 on Thursday as the company said it has been named as sponsor related to 4 SPACs. Takung Art Co., Ltd. (... 
Via Benzinga
Why Selecta Biosciences Stock Is Dropping Today
The progress of one of the company's clinical programs is being delayed. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Galera Therapeutics (NASDAQ:GRTX) stock rose 21.78% to $8.05 during Thursday's regular session. As of 12:32 EST, Galera Therapeutics's stock is trading at... 
Via Benzinga
54 Stocks Moving In Thursday's Mid-Day Session
Gainers Willamette Valley Vineyards, Inc. (NASDAQ: WVVI) climbed 40.5% to $14.39. Dolphin Entertainment, Inc. (NASDAQ: DLPN) shares gained 23.1% to $14.14. Dolphin Entertainment... 
Via Benzinga
Selecta Biosciences Stock Is Trading Lower After Gaining Total Rights To MMA Program From AskBio
Based on an internal strategic review and prioritization of its portfolio, Asklepios BioPharmaceutical Inc (AskBio) has decided to give all rights of... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.